[go: up one dir, main page]

DE60144204D1 - 84P2A9: Prostata- und hodenspezifisches Protein, das sehr stark bei Prostatakrebs vorkommt - Google Patents

84P2A9: Prostata- und hodenspezifisches Protein, das sehr stark bei Prostatakrebs vorkommt

Info

Publication number
DE60144204D1
DE60144204D1 DE60144204T DE60144204T DE60144204D1 DE 60144204 D1 DE60144204 D1 DE 60144204D1 DE 60144204 T DE60144204 T DE 60144204T DE 60144204 T DE60144204 T DE 60144204T DE 60144204 D1 DE60144204 D1 DE 60144204D1
Authority
DE
Germany
Prior art keywords
prostate
common
fragment
cancers
encoded protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60144204T
Other languages
English (en)
Inventor
Aya Jakobovits
Daniel E H Afar
Pia M Challita-Eid
Elana Levin
Steve Chappell Mitchell
Rene S Hubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Application granted granted Critical
Publication of DE60144204D1 publication Critical patent/DE60144204D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60144204T 2000-01-26 2001-01-26 84P2A9: Prostata- und hodenspezifisches Protein, das sehr stark bei Prostatakrebs vorkommt Expired - Lifetime DE60144204D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17856000P 2000-01-26 2000-01-26

Publications (1)

Publication Number Publication Date
DE60144204D1 true DE60144204D1 (de) 2011-04-21

Family

ID=22653018

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60144204T Expired - Lifetime DE60144204D1 (de) 2000-01-26 2001-01-26 84P2A9: Prostata- und hodenspezifisches Protein, das sehr stark bei Prostatakrebs vorkommt
DE60133627T Expired - Lifetime DE60133627T2 (de) 2000-01-26 2001-01-26 84p2a9: prostata- und testis-spezifisches protein das hohe expression in prostatakrebs aufweist

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60133627T Expired - Lifetime DE60133627T2 (de) 2000-01-26 2001-01-26 84p2a9: prostata- und testis-spezifisches protein das hohe expression in prostatakrebs aufweist

Country Status (12)

Country Link
US (3) US7510855B2 (de)
EP (2) EP1967586B1 (de)
JP (2) JP3946044B2 (de)
AT (2) ATE501255T1 (de)
AU (2) AU2001237973B2 (de)
CA (1) CA2398064C (de)
CY (1) CY1111522T1 (de)
DE (2) DE60144204D1 (de)
DK (1) DK1967586T3 (de)
ES (2) ES2360155T3 (de)
IL (2) IL150873A0 (de)
WO (1) WO2001055391A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2360155T3 (es) 2000-01-26 2011-06-01 Agensys, Inc. 84p2a9: una proteína específica de próstata y testículos altamente expresada en el cáncer de próstata.
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (da) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
WO2014039014A1 (en) * 2012-09-07 2014-03-13 Agency For Science, Technology And Research Peptides and their uses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
CN1195851C (zh) 1997-02-25 2005-04-06 科里克萨有限公司 用于前列腺癌免疫疗法的化合物及其用途
WO1998045435A2 (en) 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
JP2002519000A (ja) 1998-01-28 2002-07-02 カイロン コーポレイション ヒト遺伝子および遺伝子発現産物ｉｉ
US6013450A (en) 1998-02-20 2000-01-11 Incyte Pharmaceuticals, Inc. CAF1-related protein
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
EP1074617A3 (de) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers für Synthese von ganzen-Länge cDNS und deren Anwendung
AU2001229340A1 (en) 2000-01-14 2001-07-24 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
ES2360155T3 (es) * 2000-01-26 2011-06-01 Agensys, Inc. 84p2a9: una proteína específica de próstata y testículos altamente expresada en el cáncer de próstata.
CA2394039A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1274714A2 (de) 2000-04-06 2003-01-15 Genetics Institute, LLC Polynukleotide, die neue sekretierte proteine kodieren
CN1328147A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——人磷脂酶49.06和编码这种多肽的多核苷酸
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
WO2002010449A2 (en) 2000-07-28 2002-02-07 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
WO2002022660A2 (en) 2000-09-11 2002-03-21 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2425827A1 (en) 2000-10-12 2002-04-18 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2002253878A1 (en) 2001-01-25 2002-08-06 Gene Logic, Inc. Gene expression profiles in breast tissue

Also Published As

Publication number Publication date
EP1967586A1 (de) 2008-09-10
EP1250434A2 (de) 2002-10-23
CA2398064A1 (en) 2001-08-02
US8013126B2 (en) 2011-09-06
AU2001237973B2 (en) 2006-09-07
CA2398064C (en) 2012-12-18
IL150873A0 (en) 2003-02-12
AU3797301A (en) 2001-08-07
ES2304126T3 (es) 2008-09-16
DE60133627T2 (de) 2009-07-30
EP1250434B1 (de) 2008-04-16
ATE501255T1 (de) 2011-03-15
US7582448B2 (en) 2009-09-01
DK1967586T3 (da) 2011-06-20
JP2006325595A (ja) 2006-12-07
ATE392474T1 (de) 2008-05-15
US7510855B2 (en) 2009-03-31
WO2001055391A2 (en) 2001-08-02
US20070054363A1 (en) 2007-03-08
WO2001055391A3 (en) 2002-02-21
DE60133627D1 (de) 2008-05-29
JP2003520605A (ja) 2003-07-08
US20040126862A1 (en) 2004-07-01
IL150873A (en) 2010-02-17
ES2360155T3 (es) 2011-06-01
EP1967586B1 (de) 2011-03-09
JP3946044B2 (ja) 2007-07-18
US20090170191A1 (en) 2009-07-02
JP5501550B2 (ja) 2014-05-21
CY1111522T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
ATE420175T1 (de) C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
NO20004631D0 (no) Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft
PL354348A1 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2003083041A3 (en) Cripto-specific antibodies
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
TNSN05300A1 (en) Treatment with anti-vegf antibodies
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
DE60144204D1 (de) 84P2A9: Prostata- und hodenspezifisches Protein, das sehr stark bei Prostatakrebs vorkommt
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
AU2001233912A1 (en) Diagnosis of breast cancer using bcmp-81 as marker
DE60326931D1 (de) In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
ATE403716T1 (de) Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
WO2003020954A3 (en) 205p1b5 in treatment and detection of cancer
WO2001059110A3 (en) 34p3d7: a tissue specific protein highly expressed in prostate cancer
WO2003042700A3 (en) Breast cancer associated polypeptide
WO2001059115A3 (en) 83p5g4: a tissue specific protein highly expressed in prostate cancer
ATE490981T1 (de) Criptospezifische antikörper